North America Urinary Tract Infection Testing Market Size, Share & Trends Analysis Report By Type (Urethritis, Cystitis, Pyelonephritis), By Product, By End-use (Reference Laboratories, General Practitioners), By Country, And Segment- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The North America urinary tract infection testing market size was estimated at USD 206.26 million in 2022 and is expected to surpass around USD 308.26 million by 2032 and poised to grow at a compound annual growth rate (CAGR) of 4.1% during the forecast period 2023 to 2032.

North America Urinary Tract Infection Testing Market Size, 2023

Key Takeaways:

  • The cystitis segment accounted for the largest revenue share of 42.26% in 2022 in the North America urinary tract infection testing market.
  • The pyelonephritis segment is expected to witness the fastest CAGR over the forecast period.
  • The instruments segment accounted for the largest revenue share of 61.16% in 2022 and is expected to witness the fastest CAGR over the forecast period.
  • The reference laboratories segment held the largest revenue share of 27.9% in 2022.
  • The urogynecologists segment is expected to witness the fastest CAGR over the forecast period.
  • The U.S. dominated the North American market for urinary tract infection testing in 2022 with 91.16% of the revenue share.

North America Urinary Tract Infection Testing Market Report Scope

Report Attribute Details
Market Size in 2023 USD 214.72 Million
Market Size by 2032 USD 308.26 Million
Growth Rate From 2023 to 2032 CAGR of 4.1%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Type, Product, End-use, Country
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled QIAGEN; Accelerate Diagnostics, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; Danaher Corporation; Siemens Healthcare GmbH; Randox Laboratories Ltd.; Thermo Fisher Scientific, Inc.; bioMérieux SA; T2 Biosystems, Inc.

 

The increasing prevalence of Urinary Tract Infections (UTIs), the aging population, increasing awareness about the importance of early UTI detection, and better access to healthcare facilities are some of the major factors driving the growth of the market in the region. Moreover, engaging in sexual intercourse and using spermicides and diaphragms can increase the risk of developing UTIs. Frequent pelvic exams and anatomical abnormalities of the urinary tract can also make someone more susceptible to UTIs.

Urinary tract infection is becoming a common global concern. According to data published by the National Library of Medicine, Urinary tract infections (UTIs) are common bacterial infections among women in the U.S., typically affecting those between 16 and 35 years of age. About 10% of women experience a UTI each year, and 40-60% will have at least one infection in their lifetime. Recurrences are frequent, with nearly half experiencing a second infection within a year. UTIs are more prevalent in females, occurring at least four times more frequently than males. Moreover, even with appropriate antibiotic treatment, UTI symptoms can persist for several days. For women with recurring UTIs, their quality of life may be negatively affected. Approximately 25% of women experience such recurrences within six months.

The rising incidence of UTIs in the elderly is significantly impacting the market growth in the region. With a substantial portion of the aging population susceptible to UTIs, there is an increasing demand for advanced UTI testing and treatment solutions. As people age, their vulnerability to UTIs increases due to weakened bladder and pelvic floor muscles, which can lead to urine retention or incontinence. When urine remains in the urinary tract, it creates an environment where bacteria, such as E. coli, can multiply and cause infections. Seniors are at higher risk of UTIs due to factors like weakened immune systems, the use of catheters, diabetes, and kidney problems.

In older women, UTIs are more common due to changes in the female anatomy and lower estrogen levels after menopause. This hormonal shift can lead to an imbalance of bacteria in the vagina, increasing the likelihood of an infection. UTIs are less prevalent in older men due to the male anatomy, but uncircumcised men or those with enlarged prostates (BPH) are susceptible. UTIs associated with BPH occur when the bladder is not fully emptied. Proper understanding and management of these risk factors are essential to prevent and address UTIs in older adults.

Furthermore, the increasing prevalence of catheter-associated UTIs (CAUTIs) is driving the growth of the market for UTI testing solutions. Healthcare facilities and providers recognize the urgent need for accurate and timely UTI testing to identify and manage CAUTIs effectively. As the incidence of CAUTIs rises, there is a growing demand for advanced UTI testing instruments to detect and quantify pathogens, including drug-resistant strains. Catheter-associated UTIs (CAUTIs) are the most prevalent healthcare-associated infections in hospitals and long-term health facilities.

Short-term catheter use increases CAUTI risk by 3-7% each day, leading to an up to 80% higher risk of complications during hospitalization. For long-term catheterization, the risk of complications is nearly 100%. CAUTIs are linked to higher morbidity and mortality rates and are a primary cause of secondary bacteremia. The use of urinary catheters bypasses the body's natural immune defense, providing microorganisms from the groin and perineum with direct access to the bladder. The persistent irritation and inflammation caused by catheters in the bladder hinder normal bladder contraction and urination, making the bladder more susceptible to infection.

Increasing R&D for developing advanced UTI testing kits is driving the growth of the market in North America. Companies and research institutions are investing in innovative technologies and improved diagnostic sensors to improve the early detection and accuracy of UTIs. These advancements in UTI testing kits enable quicker and more reliable diagnosis, leading to better patient outcomes and more effective treatments. For instance, in May 2023, The University of Texas at Dallas unveiled a prototype diagnostic sensor that can rapidly confirm urinary tract infections (UTIs), without waiting for 24 to 48 hours for lab test results.

This innovative technology leverages the diagnostic capability of electrochemical biosensors, leading to more accurate therapy and better patient outcomes. Continuous efforts to enhance the performance and efficiency of UTI testing kits are attracting healthcare providers and consumers, driving market growth in the region. Moreover, the rising awareness about the importance of early UTI detection and the potential benefits of advanced testing kits encourage higher adoption rates among healthcare facilities, further contributing to North America's urinary tract infection testing market expansion.

Type Insights

The cystitis segment accounted for the largest revenue share of 42.26% in 2022 in the North America urinary tract infection testing market. Cystitis is a condition where bacteria from the skin or bowel enter the urethra and bladder, leading to irritation and inflammation of the bladder lining, causing a bladder infection. There are two types of cystitis - acute, which occurs suddenly; and interstitial, a chronic and longer-term condition. The growth of the segment is due to the rising incidence & recurrence rate of cystitis, the increased number of product approvals, and the high number of diabetes patients more prone to cystitis.

The pyelonephritis segment is expected to witness the fastest CAGR over the forecast period. This is owing to the increasing cases of pyelonephritis in the region. According to NCBI statistics, each year, there are approximately 250,000 cases of pyelonephritis in the U.S., with a higher occurrence among females. Among women aged between 18 to 49 years, the estimated incidence of pyelonephritis is 28 cases per 10,000 individuals, and around 7% of these cases require hospital admission. Recurrence is less frequent than uncomplicated UTIs, with 9% of females and 5.7% of males experiencing a second episode within a year.

Product Insights

The instruments segment accounted for the largest revenue share of 61.16% in 2022 and is expected to witness the fastest CAGR over the forecast period. The rising prevalence of UTIs in North America has led to a greater demand for efficient and reliable testing methods. Instruments are crucial in UTI testing as they are essential for accurate and rapid diagnosis. Advanced diagnostic instruments, such as automated urine analyzers and point-of-care testing devices, have gained traction due to their ability to deliver faster and more precise results. These instruments aid in detecting UTIs early, allowing for prompt treatment and improved patient outcomes.

Additionally, ongoing advancements in diagnostic technologies have led to the development of sophisticated instruments with enhanced capabilities. For instance, the increasing adoption of innovative UTI testing instruments, such as the Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP), is revolutionizing the UTI testing market in the region. These advanced instruments offer greater accuracy and sensitivity, attracting healthcare providers and driving market growth.

End-use Insights

The reference laboratories segment held the largest revenue share of 27.9% in 2022. Reference laboratories offer a wide range of comprehensive testing services, including UTI testing, to healthcare providers. These laboratories have advanced instruments and technologies to perform various diagnostic tests with high accuracy and efficiency. Moreover, many reference laboratories have multiple locations and wide geographic coverage, enabling them to serve a large population across different states and regions in North America. In addition, reference labs can handle large volumes of diagnostic tests at an expedited rate and provide better results at comparatively lower prices, which is anticipated to offer economies of scale to service providers.

The urogynecologists segment is expected to witness the fastest CAGR over the forecast period. Urogynecologists primarily focus on women's health concerns, including conditions that affect the urinary tract. Since UTIs are more prevalent in women, urogynecologists encounter and manage UTI cases more frequently than other healthcare specialists. They also perform specific tests to identify the underlying cause of recurrent UTIs and recommend appropriate treatment plans. This comprehensive approach to UTI diagnosis and management may contribute to the growth of UTI testing services within the urogynecology segment.

Country Insights

The U.S. dominated the North American market for urinary tract infection testing in 2022 with 91.16% of the revenue share. The presence of key players such as Abbott, BIOMERIEUX, BD, Siemens Healthineers AG, QIAGEN, Accelerate Diagnostics, Inc., Bio-Rad Laboratories, Inc., and Quest Diagnostics is positively influencing market growth. Moreover, increasing R&D initiatives by the key players in the region is expected to drive market growth further.

For instance, in June 2023, Pathnostics, a U.S.-based precision diagnostic testing and development company, unveiled two new studies showcasing the favorable results of its advanced urinary tract infection (UTI) test. The research revealed that treatment guided by the company's Guidance UTI test reduced healthcare resource usage and expenses when compared to standard urine culture (SUC) tests.

On the other hand, Canada is estimated to witness the fastest growth rate over the coming years. This is owing to the rising awareness about UTI control among the country’s population and increasing initiatives by regional government authorities. For instance, in December 2019, the Canadian government introduced the Urinary Tract Infection (UTI) program to address the issue of excessive antibiotic use for suspected UTIs in long-term care homes (LTCHs) and the resulting risks associated with antibiotics.

The UTI program assists long-term care homes in enhancing the management of UTIs for residents without catheters, guiding them in implementing necessary organizational and individual practice improvements. The program aims to optimize UTI testing and treatment protocols, promoting better healthcare outcomes while minimizing antibiotic-related complications.

Key Companies & Market Share Insights

Major companies operating in the regional urinary tract infection testing market are attempting to enhance their product portfolio by upgrading their products and exploring acquisitions and government authorizations to increase their client base and obtain a larger market share. For instance, in May 2023, PathogenDx, a manufacturer and provider of diagnostic solutions, announced that it is preparing to launch an advanced microarray-based test designed specifically for urinary tract infections (UTIs). The UTI assay will be able to identify 26 pathogens and 20 associated antimicrobial resistance genes simultaneously in one comprehensive test. Some of the prominent players in the North America urinary tract infection testing market include:

  • QIAGEN
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • bioMérieux SA
  • T2 Biosystems, Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the North America Urinary Tract Infection Testing market.

By Type 

  • Urethritis
  • Cystitis
  • Pyelonephritis

By Product 

  • Instruments
  • Consumables

By End-use 

  • General practitioners
  • Urologists
  • Urogynecologists
  • Hospital Laboratories
  • Reference Laboratories
  • Hospital Emergency Departments
  • Urgent Care
  • Others

By Regional 

  • North America
    • U.S.
    • Canada

Frequently Asked Questions

The North America urinary tract infection testing market size was estimated at USD 206.26 million in 2022 and is expected to surpass around USD 308.26 million by 2032

The North America Urinary Tract Infection Testing market is growing at a compound annual growth rate (CAGR) of 4.1% from 2023 to 2032.

QIAGEN; Accelerate Diagnostics, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; Danaher Corporation; Siemens Healthcare GmbH; Randox Laboratories Ltd.; Thermo Fisher Scientific, Inc.; bioMérieux SA; T2 Biosystems, Inc.

Chapter 1. Methodology and Scope

                   1.1. Market Segmentation and Scope

                       1.1.1. Segment Definitions

                           1.1.1.1. Type segment

                           1.1.1.2. Product segment

                           1.1.1.3. End-user segment

                   1.2. Regional Scope

                   1.3. Estimates and Forecast Timeline

                   1.4. Objectives

                       1.4.1. Objective - 1

                       1.4.2. Objective - 2

                       1.4.3. Objective - 3

                   1.5. Research Methodology

                   1.6. Information Procurement

                       1.6.1. Purchased Database

                       1.6.2. Nova one advisor Internal Database

                       1.6.3. Secondary Sources

                       1.6.4. Primary research

                   1.7. Information or Data Analysis

                       1.7.1. Data Analysis Models

                   1.8. Market Formulation & Validation

                   1.9. Model Details

                       1.9.1. Commodity Flow Analysis

                   1.10. List of Secondary Sources

                   1.11. List of Abbreviations

Chapter 2. Executive Summary

                   2.1. Market Snapshot

                   2.2. Product and Type Snapshot

                   2.3. End-use Snapshot

                   2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

                   3.1. Market Lineage Outlook

                       3.1.1. Parent Market Outlook

                       3.1.2. Related/Ancillary Market Outlook

                   3.2. Market Dynamics

                       3.2.1. Market Driver Analysis

                           3.2.1.1. Increasing prevalence of urinary tract infections (UTIs)

                           3.2.1.2. Technological Advancements in Urinary Tract Infection Testing

                           3.2.1.3. Growing prevalence of catheter-associated UTIs (CAUTIs)

                       3.2.2. Market Restraint Analysis

                           3.2.2.1. High cost associated with advanced UTI testing technologies.

                   3.3. Industry Analysis Tools

                       3.3.1. Porter’s Five Forces Analysis

                       3.3.2. PESTEL Analysis

                       3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Urinary Tract Infection Testing Market: Type Analysis

                   4.1. North America Urinary Tract Infection Testing Market: Type Movement Analysis

                   4.2. Urethritis

                       4.2.1. Urethritis Market, 2020 - 2032

                   4.3. Cystitis

                       4.3.1. Cystitis Market, 2020 - 2032

                   4.4. Pyelonephritis

                       4.4.1. Pyelonephritis Market, 2020 - 2032

Chapter 5. North America Urinary Tract Infection Testing Market: Product Analysis

                   5.1. North America Urinary Tract Infection Testing Market: Product Movement Analysis

                   5.2. Instruments

                       5.2.1. Instruments Market, 2020 - 2032

                   5.3. Consumables

                       5.3.1. Consumables Market, 2020 - 2032

Chapter 6. North America Urinary Tract Infection Testing Market: End-use Analysis

                   6.1. North America Urinary Tract Infection Testing Market: End-use Movement Analysis

                   6.2. General Practitioners

                       6.2.1. General Practitioners Market, 2020 - 2032

                   6.3. Urologists

                       6.3.1. Urologists Market, 2020 - 2032

                   6.4. Urogynecologists

                       6.4.1. Urogynecologists Market, 2020 - 2032

                   6.5. Hospital Laboratories

                       6.5.1. Hospital Laboratories Market, 2020 - 2032

                   6.6. Reference Laboratories

                       6.6.1. Reference Laboratories Market, 2020 - 2032

                   6.7. Hospital Emergency Departments

                       6.7.1. Hospital Emergency Departments Market, 2020 - 2032

                   6.8. Urgent Care

                       6.8.1. Urgent Care Market, 2020 - 2032

                   6.9. Others

                       6.9.1. Others Market, 2020 - 2032

Chapter 7. North America Urinary Tract Infection Testing Market: Regional Analysis

                   7.1. North America

                       7.1.1. SWOT Analysis

                       7.1.2. North America Urinary Tract Infection Testing Market, 2020 - 2032

                       7.1.3. U.S.

                           7.1.3.1. Key Country Dynamics

                           7.1.3.2. Target Disease Prevalence

                           7.1.3.3. Competitive Scenario

                           7.1.3.4. Regulatory Framework

                           7.1.3.5. U.S. Urinary Tract Infection Testing Market, 2020 - 2032

                       7.1.4. Canada

                           7.1.4.1. Key Country Dynamics

                           7.1.4.2. Target Disease Prevalence

                           7.1.4.3. Competitive Scenario

                           7.1.4.4. Regulatory Framework

                           7.1.4.5. Canada Urinary Tract Infection Testing Market, 2020 - 2032

Chapter 8. Competitive Landscape

                   8.1. Participant Categorization

                       8.1.1. QIAGEN

                           8.1.1.1. Overview

                           8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.1.3. Product Benchmarking

                           8.1.1.4. Strategic Initiatives

                       8.1.2. Accelerate Diagnostics, Inc.

                           8.1.2.1. Overview

                           8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.2.3. Product Benchmarking

                           8.1.2.4. Strategic Initiatives

                       8.1.3. Bio-Rad Laboratories, Inc.

                           8.1.3.1. Overview

                           8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.3.3. Product Benchmarking

                           8.1.3.4. Strategic Initiatives

                       8.1.4. F. Hoffmann-La Roche Ltd.

                           8.1.4.1. Overview

                           8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.4.3. Product Benchmarking

                           8.1.4.4. Strategic Initiatives

                       8.1.5. Danaher Corporation

                           8.1.5.1. Overview

                           8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.5.3. Product Benchmarking

                           8.1.5.4. Strategic Initiatives

                       8.1.6. Siemens Healthcare GmbH

                           8.1.6.1. Overview

                           8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.6.3. Product Benchmarking

                           8.1.6.4. Strategic Initiatives

                       8.1.7. Randox Laboratories Ltd.

                           8.1.7.1. Overview

                           8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.7.3. Product Benchmarking

                           8.1.7.4. Strategic Initiatives

                       8.1.8. Thermo Fisher Scientific, Inc.

                           8.1.8.1. Overview

                           8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.8.3. Product Benchmarking

                           8.1.8.4. Strategic Initiatives

                       8.1.9. bioMérieux SA

                           8.1.9.1. Overview

                           8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.9.3. Product Benchmarking

                           8.1.9.4. Strategic Initiatives

                       8.1.10. T2 Biosystems, Inc.

                           8.1.10.1. Overview

                           8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)

                           8.1.10.3. Product Benchmarking

                           8.1.10.4. Strategic Initiatives

                   8.2. Participant’s Overview

                   8.3. Financial Performance

                   8.4. Product Benchmarking

                   8.5. Company Market Share Analysis, 2022

                   8.6. Strategy Mapping

                       8.6.1. Expansions

                       8.6.2. Acquisitions

                       8.6.3. Product/Service Launches

                       8.6.4. Others

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers